European Union Pharmaceutical Industry Package
In December 2025, negotiators reached a historic political agreement on a major overhaul of drug laws known as the EU pharma package. As these massive new rules roll out across Europe, pharmaceutical companies face a complicated double reality. They must adapt to a unified European market while simultaneously managing messy, localized differences from country-specific ethics boards and regional testing requirements.
Understanding the New ICH-M14 Safety Guidelines
Today, the pharmaceutical industry is moving toward a massive transformation. A historic change occurred when a global organization called the International Council for Harmonization officially adopted a new framework named the ICH M14 guideline. This framework changes the rulebook for drug safety.
ICH Q12: Post-Approval Change Management for Pharmaceutical Product Lifecycle Management
The formalized roll-out of ICH Q12 mechanisms introduces an organized approach to identifying and managing regulatory commitments. This framework allows manufacturers to execute routine modifications under the oversight of their internal Pharmaceutical Quality System (PQS), reducing the burden of prior-approval regulatory filings.